Seeking Alpha: argenx targets 12,000 CIDP patients with VYVGART expansion in 2025 Seeking Alpha: Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options This week, we are going to continue down the road of autoimmune peripheral nerve conditions to discuss two that we have touched on in the past—Guillain-Barré Syndrome and CIDP (chronic inflammatory ... Yahoo Finance: Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP The FDA on March 16 approved CSL Behring’s drug Hizentra to treat chronic inflammatory demyelinating polyneuropathy. Hizentra is the first subcutaneous immunoglobulin approved to treat CIDP, a rare ...

Understanding the Context

WAYNE, Pennsylvania (WPVI) -- One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get back on their feet. A great place to see their ...